ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Arbutus Biopharma (ABUS)
Arbutus Biopharma stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$4.29▲ +2.14%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Arbutus Biopharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Arbutus Biopharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Arbutus Biopharma a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $4.01 and $4.59; in 9 out of 10, between $3.55 and $5.17. Estimated annual volatility is 35%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $882M
- P/E ratio
- 5.8
- 52-week high
- $5.45
- 52-week low
- $3.50
- Revenue (12 months)
- $182M
- Revenue growth (YoY)
- +128.2%
- Gross margin
- 0.0%
- Operating margin
- -192.1%
- Net margin
- -237.9%
- Return on equity
- 89.6%
- Free cash flow (12 months)
- $-80.2M
- Beta
- 0.62
What this means
ATLAS does not publish a fair value for ABUS right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks ABUS has traded between $3.50 and $5.45. Today it is 21.3% below that high and 23% above its low.
On the business: revenue grew 128.2% year over year; net margin is 237.9%; it trades at 5.8 times earnings.
Its beta is 0.62: it tends to move less than the market.
About the company
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection.
Want to see everything about Arbutus Biopharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Arbutus Biopharma do?
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection.
What is the chance ABUS goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, ABUS ends the month between $4.01 and $4.59.
How big is Arbutus Biopharma and what is its P/E ratio?
Arbutus Biopharma's market capitalization is $882M. Its price-to-earnings (P/E) ratio is 5.8: you pay $5.8 for each $1 of yearly earnings.
How volatile is ABUS?
ATLAS estimates annual volatility at 35%. In a typical month, half of the outcomes end between $4.01 and $4.59.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer